Literature DB >> 27555541

Antidepressant-like effects of long-term sarcosine treatment in rats with or without chronic unpredictable stress.

Kuang-Ti Chen1, Ching-Hsiang Wu2, Mang-Hung Tsai3, Ya-Chieh Wu4, Ming-Jia Jou5, Chih-Chia Huang6, I-Hua Wei7.   

Abstract

Sarcosine, an N-methyl-d-aspartate receptor enhancer, can improve depression-like behavior in rodent models and depression in humans. We found that a single dose of sarcosine exerted antidepressant-like effects with rapid concomitant increases in the mammalian target of rapamycin (mTOR) signaling pathway activation and enhancement of α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor (AMPAR) membrane insertion. Sarcosine may play a crucial role in developing novel therapy for depression. For a detailed understanding of sarcosine, this study examined the effects of long-term sarcosine treatment on the forced swim test (FST), mTOR signaling, and AMPAR membrane insertion in rats. The effects of long-term sarcosine treatment were examined in naive rats and rats exposed to chronic unpredictable stress (CUS). Long-term sarcosine treatment (560mg/kg/d for 21 d) significantly ameliorated the increased immobility induced by CUS in the FST, reaffirming the potential role of sarcosine as an antidepressant for depressed patients. The same long-term treatment exhibited no such effect in naive rats despite increased mTOR activation and AMPAR membrane insertion in both groups. Our findings clearly show CUS-exposed rats are sensitive to long-term sarcosine treatment in FST and the response at the same dose is absent in naïve rats. Nevertheless, the distinct sensitivity to long-term sarcosine treatment in rats with or without CUS is not associated with the activated mTOR signaling pathway or increased AMPAR membrane insertion. Additionally, understanding the behavioral and molecular basis of distinct responses is vital important for developing personalized treatment programs to increase the probability of success when treating depression.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  AMPA; Depression; Long-term treatment; Sarcosine; mTOR

Mesh:

Substances:

Year:  2016        PMID: 27555541     DOI: 10.1016/j.bbr.2016.06.004

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  8 in total

1.  Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents.

Authors:  Octavian Vasiliu
Journal:  Front Pharmacol       Date:  2022-06-17       Impact factor: 5.988

2.  Sarcosine Is Uniquely Modulated by Aging and Dietary Restriction in Rodents and Humans.

Authors:  Ryan O Walters; Esperanza Arias; Antonio Diaz; Emmanuel S Burgos; Fangxia Guan; Simoni Tiano; Kai Mao; Cara L Green; Yungping Qiu; Hardik Shah; Donghai Wang; Adam D Hudgins; Tahmineh Tabrizian; Valeria Tosti; David Shechter; Luigi Fontana; Irwin J Kurland; Nir Barzilai; Ana Maria Cuervo; Daniel E L Promislow; Derek M Huffman
Journal:  Cell Rep       Date:  2018-10-16       Impact factor: 9.423

Review 3.  New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.

Authors:  Yu-Jhen Huang; Hsien-Yuan Lane; Chieh-Hsin Lin
Journal:  Neural Plast       Date:  2017-04-11       Impact factor: 3.599

Review 4.  Modulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13).

Authors:  Andrei-Nicolae Vasilescu; Nina Schweinfurth; Stefan Borgwardt; Peter Gass; Undine E Lang; Dragos Inta; Sarah Eckart
Journal:  Neuropsychiatr Dis Treat       Date:  2017-03-31       Impact factor: 2.570

Review 5.  Enhancing NMDA Receptor Function: Recent Progress on Allosteric Modulators.

Authors:  Lulu Yao; Qiang Zhou
Journal:  Neural Plast       Date:  2017-01-09       Impact factor: 3.599

Review 6.  Beyond Ketamine: New Approaches to the Development of Safer Antidepressants.

Authors:  Shigeyuki Chaki
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 7.  Glutamatergic System in Depression and Its Role in Neuromodulatory Techniques Optimization.

Authors:  Mohamed Adil Shah Khoodoruth; Maria Anayali Estudillo-Guerra; Kevin Pacheco-Barrios; Azan Nyundo; Gina Chapa-Koloffon; Sami Ouanes
Journal:  Front Psychiatry       Date:  2022-04-14       Impact factor: 5.435

8.  Post-weaning A1/A2 β-casein milk intake modulates depressive-like behavior, brain μ-opioid receptors, and the metabolome of rats.

Authors:  Aya Osman; Simone Zuffa; Gemma Walton; Elizabeth Fagbodun; Panos Zanos; Polymnia Georgiou; Ian Kitchen; Jonathan Swann; Alexis Bailey
Journal:  iScience       Date:  2021-08-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.